Solid Tumor Terminated Phase 1 Trials for Tislelizumab (DB14922)

Back to Solid Tumor

Also known as: Cancer - Solid Tumors / Solid Tumour / Solid Tumours / Tumor, Solid / Solid Neoplasms / Solid tumour/cancer / Solid Cancers / Cancer: Solid Tumors / Neoplasms, Solid Tumor / Cancer, Solid Tumor / Tumors, Solid / Solid Tumor Cancer / Solid Tumors or Cancers / Solid Tumors / Solid Neoplasm / Cancer (Solid Tumors) / Solid Tumor Neoplasms / Solid Tumor Cancers / Solid Cancer / Neoplasm / Neoplasm (morphologic abnormality) / Neoplasms of unspecified behavior / Neoplasms NOS / Neoplasms NOS (disorder) / [M]Neoplasms NOS (morphologic abnormality) / Neoplasm (NOS) / Tumor / Neoplasm NOS / Tumour / Tumour NOS / Neoplasms / Tumour, NOS / Tumor NOS / Neoplasm, NOS / Tumor, NOS / Neoplasms benign, malignant and unspecified (incl cysts and polyps)

IndicationStatusPhase
DBCOND0030180 (Solid Tumor)Terminated1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT05494762
Safety, Pharmacokinetics, and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab (BGB-A317) in Participants With Advanced Solid TumorsTreatment
NCT05581719
A Phase 1/2a Study Evaluating Allocetra-OTS as Monotherapy or in Combination With Anti-PD-1 Therapy for the Treatment of Advanced Solid Tumor MalignancyTreatment
NCT06487858
A Study of BGB-R046 as Monotherapy and in Combination With Tislelizumab in Solid TumorsTreatment
NCT05935098
BGB-A3055 Alone and in Combination With Tislelizumab in Participants With Solid TumorsTreatment
NCT06585488
A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or AmplificationTreatment
NCT04261439
A Phase I/Ib Study of NIZ985 Alone and in Combination With SpartalizumabTreatment
NCT04577963
A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid TumorsTreatment